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OBJECTIVES: Denosumab is a human monoclonal antibody against receptor acti-
vator of nuclear factor-kB ligand (RANKL), which can be used for osteoporosis as an 
antiresorptive agent. The aim of this study was to evaluate the efficacy and safety 
of denosumab for the treatment of postmenopausal osteoporosis by performing 
a meta-analysis. METHODS: Pubmed, EMBASE, the Cochrane Central Register 
of Controlled Trials, and other trial registries through July 2014 were searched. 
Inclusion criteria were randomized, placebo-controlled clinical trials on patients 
with postmenopausal osteoporosis, 60mg of denosumab every 6 months, con-
sistent time framework, and derivable outcomes for incidences of new vertebral, 
nonvertebral fractures, and adverse events. A meta-analysis using fixed-effects 
model was conducted to calculate pooled relative risks with a 95% confidence 
interval. Heterogeneity across studies was also assessed. RESULTS: Six RCTs 
involving 9134 patients were included. The results showed that denosumab was 
associated with a significant reduction in new vertebral fractures risk (RR= 0.325, 
95%CI 0.256 to 0.412, p< 0.001). A decreased risk of nonvertebral fractures was also 
observed (RR= 0.789, 95%CI 0.670 to 0.928, p= 0.004). As compared to the placebo 
arm, the denosumab arm showed no evidence of significant risk of total adverse 
events [RR= 1.003, 95%CI 0.991 to 1.015], serious adverse events [RR= 1.042, 95%CI 
0.967 to 1.124], and fatal adverse events [RR= 0.785, 95%CI 0.557 to 1.067]. In addi-
tion, the incidence rates of all treatment-related adverse events and dropouts 
due to adverse events were not significant between the denosumab and placebo 
arms. CONCLUSIONS: The efficacy of denosumab on fracture risk reduction and 
its safety has not yet been systematically proved. However, results of this meta-
analysis showed that denosumab was associated with a significant reduction in 
the risk of vertebral and nonvertebral fractures in patients with postmenopausal 
osteoporosis. No evidence of increased risk in serious, fatal and all treatment-
related adverse events were detected.
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OBJECTIVES: Describe the adverse drug reactions (ADR) and their incidence in 
patients with rheumatoid arthritis who were treated in the Colombian Heath 
System. METHODS: Retrospective cohort study using information from all 
patients who were diagnosed with rheumatoid arthritis and attended Specialized 
Institution centers in the cities of Bogotá, Cali, Manizales, Medellin and Pereira 
between December 1st, 2009 and August 30th, 2013. The ADRs were obtained from 
medical records and the pharmacovigilance system register and were sorted by 
frequency and affected tissue according to WHO Adverse Reaction Terminology 
(WHO-ART). RESULTS: A total of 949 ADR reports were obtained from 419 patients 
with an incidence of 32.8 ADRs per 100 patient-years; these were from a cohort 
of 1,364 users followed for an average of 23.8±12.9 months. There was a female 
preponderance (n= 366, 87.4%) and a mean age of 52.7±13.1 years. The high-
est incidence rates for ADRs were reported for tocilizumab, rituximab and inf-
liximab with 28.8, 23.1 and 13.3 reports per 100 patient-years respectively. The 
most frequent were “Elevated transaminase levels” and “Dyspepsia”. Overall, 
87.7% of ADRs were type A; 36.6% were classified as mild, 40.7% as moderate 
and 22.7% were severe. As a result, 73.2% of patients who experienced an ADR 
stopped taking their drugs. CONCLUSIONS: the occurrence of ADRs in patients 
treated for rheumatoid arthritis is common, especially in those associated with 
the use of biotechnologically produced anti-rheumatic drugs. This should be 
emphasized in reports and monitoring is needed to reduce the risks in these 
patients.
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OBJECTIVES: Patients with low-energy hip fracture represent a high-risk group 
for subsequent hip fractures. Our nationwide study focused on the effect of 
demographic and clinical factors on the risk of contralateral hip fractures in 
Hungarian men over 60 years. METHODS: The retrospective observational 
cohort study based on data of the Hungarian National Health Insurance Fund. 
Men aged 60 years and over diagnosed with primary femoral neck fracture in 
year 2000 were included in the study. The incidence of contralateral fractures 
was investigated between 01 January 2000 and 31 December 2008. Occurrence of 
secondary hip fractures was analyzed in relation to patients’ age, place of living, 
hospital providing treatment for primary hip fracture, type of primary fracture, 
comorbidities, type of surgical intervention for primary fracture and survival 
time. To evaluate the prognostic factors multivariate Cox proportional hazard 
regression and Kaplan-Meier survival analysis were used. RESULTS: 917 patients 
matched the study criteria. 49 secondary fractures (5.34%) occurred during the 
observation period. The incidence density of secondary fractures was 0.13 cases 
per person-year, and the annual distribution showed that the highest incidence 
occurred in the second year (1.21%). Increasing age (years, HR: 1.06, p= 0.001, CI: 
1.02- 1.09) and place of living (town vs. village, HR: 2.82, p= 0.022, CI: 1.16- 6.84) 
were found as risk factor of subsequent hip fractures. Log rank test revealed no 
significant difference (p= 0.056) between the survival time of patients living in 
village (mean survival time: 1456 days) and in towns (mean survival time: 1481 
days). CONCLUSIONS: We demonstrated the increased risk of subsequent hip 
fracture in men with higher age and living in towns. Considering that there was 
no difference in the survival time, there is a need to identify lifestyle factors influ-
encing the incidence of subsequent hip fractures in men living in village and in 
towns.
27 systematic reviews and health technology assessments were included, 30 clinical 
trials were extracted which the control and intervention arms were treated with 
methotrexate. The results of mixed treatment comparison revealed that tofacitinib 
displays similar safety than adalimumab, certolizumab, infliximab, etanercept, goli-
mumab, rituximab, tocilizumab and abatacept in occurrence of serious adverse 
events and serious infections due to not having statistically significance differences. 
In the outcome of withdrawal due to adverse events, etanercept showed less prob-
ability of occurrence than tofacitinib (OR= 2.21, IC95%: 1.02-4.03), regarded to other 
biological DMARDs, they presented the same risk than tofacitinib. CONCLUSIONS: 
The results of mixed treatment comparison indicated that tofacitinib is similarly 
safe than biological DMARDs considering the occurrence of serious adverse events 
and serious infections.
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OBJECTIVES: Evaluate factors and reasons associated with switching from bio-
logic disease-modifying anti-rheumatic drugs (bDMARD) in Kaiser Permanente 
Southern California (KPSC) experienced RA patients; evaluate RA related health 
care resource utilization (HCRU) and costs associated with bDMARD switch-
ing. METHODS: A retrospective database study was conducted using KPSC 
patients greater than or equal to 18 years of age and with a diagnosis of RA (ICD-9 
714.xx). The identification period was from 01/01/2009 to 12/31/2012. The index 
date was defined as the first identified bDMARD prescription during the identi-
fication period. Patients were on the same index bDMARD for 24 months prior 
to index date and were followed up for 12 months post-index. Patients were cat-
egorized into a switch and a non-switch group during follow up. A multivariate 
regression analysis was conducted to evaluate factors associated with patients 
switching versus not switching. Chart notes were reviewed 30 days prior and 30 
days post switch date to identify reasons for switching. RA related HCRU and costs 
were calculated for 12 months pre/post-index for both groups. RESULTS: 1,753 
patients were identified (5% switchers, and 95% non-switchers). Factors associated 
with bDMARD switching were: obesity, Charlson comorbidity index (CCI) score ≥ 2, 
narcotics or NSAIDS use, non-adherence, and higher outpatient use in the prior 
6 months. Over 40% of patients switched due to adverse events, lack or loss of 
efficacy. Patients who switched had higher RA related pre/post-index outpatient 
visits and higher 12 months pre/post-index outpatient visit costs versus those 
patients that did not switch. CONCLUSIONS: Previous studies have evaluated 
bDMARD switching patterns in RA patients; however these unique data from this 
integrated healthcare system highlights reasons associated with bDMARD switch-
ing. Reasons associated with bDMARD switching included medication adverse 
events, and lack/loss of efficacy. RA Patients who switched bDMARD had higher 
RA related outpatient HCRU and costs.
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fActorS And reASonS ASSociAted With SWitching in rheuMAtoid 
ArthritiS PAtientS neWly initiAted on Biologic dMArdS And 
iMPAct on heAlth cAre reSource utilizAtion in A MAnAged cAre 
orgAnizAtion
Rashid N.1, Aranda G.2, Li Z.1, Guerrero V.1, Nadkarni A.2, Patel C.2
1Kaiser Permanente, SCAL Region, Downey, CA, USA, 2BMS, Plainsboro, NJ, USA
OBJECTIVES: Evaluate factors and reasons associated with switching from initial 
biologic disease-modifying anti-rheumatic drugs (bDMARDs) in Kaiser Permanente 
Southern California (KPSC) RA patients; to evaluate RA related healthcare resource 
utilization (HCRU) and cost associated with bDMARD switching. METHODS: A ret-
rospective database study from time period 01/01/2007 to 12/31/2012 was used to 
identify KPSC patient’s ≥ 18 years of age and with a diagnosis of RA (ICD-9 714.xx). 
The index date was defined as the first bDMARD prescription with no prior history 
of bDMARD use 12 months pre-index date. Patients were followed up for 12 months 
post-index and were categorized into a switch group and a non-switch group dur-
ing follow up. A multivariate regression analysis was conducted to evaluate factors 
associated with bDMARD switching. Chart notes were reviewed 30 days prior and 
30 days post bDMARD switch to identify reasons for switching. RA related HCRU 
and costs were calculated for 12 months pre/post-index for both groups. RESULTS: 
2,171 patients were identified (12% switchers, and 88% non-switchers). The aver-
age time for patients to switch was 110 days (SD + 95.5). Differences in base-
line characteristics included more use of corticosteroids, narcotics, and higher 
ER and outpatient visits in the switch group. Factors associated with bDMARD 
switching were: female gender, obesity, corticosteroids use, other conventional 
DMARD use, higher ER/outpatient use in the prior 6 months, and patients initi-
ated on Etanercept. Over 70% of patients switched due to adverse events, lack 
or loss of efficacy. Patients who switched had higher RA related cost during 12 
months pre/post-index compared to the non-switch group. CONCLUSIONS: This 
is a unique study that used robust data from an integrated healthcare system 
to evaluate reasons associated with bDMARD switching in this RA population. 
Reasons associated with bDMARD switching included medication adverse events, 
and lack/loss of efficacy; bDMARD switchers had significantly higher RA related 
costs.
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hyperlipidemia was made concurrently with the index event in 28.5% and 16.8% of 
patients, respectively. CONCLUSIONS: High SrUA appears associated with increased 
risk of hypertension; very low SrUA may also be associated with hypertension risk. 
Approximately 20% of patients were diagnosed with hypertension or hyperlipidemia 
concurrently with the gout diagnosis, suggesting that gout was the event that initiated 
recognition of these comorbidities, and that, at least in this population, healthcare 
encounters may be symptomatically driven, with lower utilization for preventive care. 
Further evaluation of the relationship between SrUA and onset of hypertension and 
hyperlipidemia is warranted.
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literAture revieW - doeS the chArActerizAtion of AxiAl SPA 
differ for Burden of illneSS BetWeen non-rAdiogrAPhic AxiAl 
SPondyloArthritiS And AnkyloSing SPondylitiS
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OBJECTIVES: Axial Spondyloarthritis (axSpA) is an inflammatory arthritic disease 
characterized by involvement of the spine, sacroiliac joints or both. Subtypes of 
axSpA include non-radiographic axial spondyloarthritis (nr-axSpA) without radio-
graphic sacroilitis confirmation, and ankylosing spondylitis (AS) with radiographic 
sacroilitis confirmation. These diseases are recognized within a spectrum of dis-
ease. Evidence suggests further stratification of nr-axSpA (e.g., MRI +/- or CRP +/-) 
may clarify the continuum of axSpA and improve clinical practice. Study objectives 
include illustrating burden of illness (BOI) similarities between the classic and fur-
ther stratified axSpA categories to suggest an improved diagnosis paradigm, and 
comparing BOI findings between nr-axSpA and AS subgroups to inform clinical 
practice. METHODS: English-language literature was searched systematically in 
Ovid SP, MEDLINE and EMBASE (2009–2014) for studies that described BOI charac-
teristics of nr-axSpA and AS including prevalence, disease activity, functioning, 
HRQL, productivity and medication utilization. PICO statement (population, inter-
vention, comparator and outcome) search terms were used. Supplementary records 
were obtained by searching American College of Rheumatology 2012 & 2013 and 
European League Against Rheumatism 2013 & 2014 scientific meeting abstracts. 
Additionally, electronic trial registries (e.g., clinicaltrials.gov), the USFDA website 
and article references were searched. RESULTS: 375 papers were retrieved and 
de-duplicated. Of the remaining 315 papers, 25 were selected per defined criteria. 
BOI in nr-axSpA and AS groups differed by gender, but were similar for all other 
categories (e.g., HRQL, functioning, productivity, etc.) indicating the two conditions 
pose a similar burden on patients. Nr-axSpA may be heterogeneous in presenta-
tion and follow a self-limiting or slowly-progressive disease course often seen in 
females (who may have lower inflammation activity). Although data for stratified 
groups (MRI+/-) within nr-axSpA was reported in one study, the evidence suggests 
similar BOI patterns. CONCLUSIONS: Future research should incorporate stratified 
nr-axSpA patient data for diagnostic comparisons and to inform clinical practice.
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OBJECTIVES: Male osteoporosis is a common but neglected public health problem. 
This may be a result of limited data evaluating the efficacy of bisphosphonates 
for fracture prevention in males. This systematic review and meta-analysis study 
assessed the efficacy of bisphosphonates versus placebo in preventing fractures 
among males. METHODS: We searched PubMed/MEDLINE, Embase, Cochrane 
Clinical Trials Library, Clinicaltrials.gov, and Scopus. All randomized placebo-con-
trolled trials of alendronate, ibandronate, risedronate, or zoledronic acid with report-
ing fracture outcomes were assessed. The trials had to include males, be at least 
one year’s duration, and utilize the United States. Food and Drug Administration 
approved bisphosphonate dosing. The outcomes of interest included clinical ver-
tebral, morphometric vertebral, non-vertebral, hip, and any fracture. Fixed-effect 
models were used in both primary and subgroup meta-analyses. Publication bias 
was examined using funnel plots and Egger’s test. Meta-regressions were conducted 
to examine age, body mass index, bone mineral density T-scores, and proportion 
of male participants on the treatment effect. A sensitivity analysis using random 
effects assumption was also conducted. RESULTS: 43 studies were included in this 
meta-analysis; 19 of them reported separate fracture for males. Bisphosphonates 
had significant effects on reducing any fractures (Total population: Relative Risk 
(RR)= 0.63, 95% Confidence Interval (CI)= 0.50-0.79; Male population: RR= 0.58, 
95%CI= 0.36-0.85) and morphometric vertebral fractures (Total population: RR= 0.45, 
95%CI= 0.32-0.63; Male population: RR= 0.40, 95%CI= 0.22-0.73). There was very little 
evidence of heterogeneity (Total population: I2= 0.0%; Male population: I2= 11.9%-
15.3%). A visual inspection of the funnel plots and the Egger’s tests (Total popu-
lation: p= 0.119; Male population: p= 0.690) indicated no evidence of publication 
bias. Moreover, meta-regression showed effect size was unrelated to male pro-
portion. There was no significant superior treatment effect on other fracture out-
comes. CONCLUSIONS: Bisphosphonates significantly reduced vertebral fracture, 
and the effect was consistent regardless of male proportions. This supports use of 
bisphosphonates in males at risk for fracture.
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coMPAriSon of diSeASe StAtuS And outcoMeS of PAtientS With 
rheuMAtoid ArthritiS (rA) receiving AdAliMuMAB or etAnercePt 
MonotherAPy in the united StAteS (uS)
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OBJECTIVES: To compare the disease status and outcomes of patients with RA 
receiving adalimumab and etanercept monotherapy in the US. METHODS: A 
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OBJECTIVES: To quantify the frequency of and excess cost associated with for-
eign objects (e.g., surgical instruments and sponges) left in the body during total 
joint arthroplasty (TJA). METHODS: Data from the 2009-2012 National/Nationwide 
Inpatient Samples (NIS) were analyzed using descriptive (i.e., frequencies and 
means) and bivariate statistical methods (i.e., t-test, chi-square, and their non-
parametric equivalents). Patients that underwent TJA were identified through 
International Classification of Diseases, 9th Revision (ICD-9) procedure codes 81.51 
(hip TJA) and 81.54 (knee TJA). Patients with retained foreign objects were identi-
fied using ICD-9 external causes of injury code E871.0. NIS sample weights were 
used to generate national incidence estimates. Costs were estimated using the 
NIS’ charge-to-cost ratio for each hospital. All costs are reported in 2014 dollars 
using Consumer Price Index adjustment factors. We were only able to quantify the 
frequency and excess cost associated with foreign objects identified and reported 
during the peri-operative period (i.e., initial hospitalization). RESULTS: Included in 
the NIS were 761,225 patients that underwent TJA during the study period. Of these 
patients, only 44 (0.01%) had a retained foreign object (20 hip TJA and 24 knee TJA); 
however, TJA patients accounted for 4.5% of all surgical patients with a hospital-
reported retained object. These TJA patients underwent one additional procedure, 
on average, than those without a retained object (p< 0.0001). We estimate the total 
annual frequency of these events at 55 TJA patients. The estimated average excess 
cost of these avoidable adverse events is $4,950 (p= 0.0068). CONCLUSIONS: Despite 
considerable effort aimed at reducing the frequency in which foreign objects are 
inadvertently left in the body during surgery, these avoidable events continue to 
occur in TJA. While retained objects are rare events in TJA, these adverse events 
lead to excess cost and procedural burden for patients. Quality improvement efforts 
should continue unitl these events are eliminated.
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OBJECTIVES: In US, falls are the leading cause of injury deaths among older adults and 
rate of fall-related deaths has risen significantly over the past decade. Medications 
with sedative or hypnotic properties are known to increase fall risk, but are frequently 
prescribed to older adults. Thus, this study aims to provide more accurate estimate 
risk of falls in older adults taking sedative-hypnotic drugs by accounting for inad-
equately addressed variables (e.g., off-label sedative-hypnotic use, and potential 
confounders not found in claims data). METHODS: Study population were commu-
nity-dwelling older adults, age > 65, with Medicare Part A, B and D coverage. In addition 
to socio-demographic, health, behavioral, and environmental factors, beneficiaries’ 
past year fall and other fall-related information were collected from 2007 and 2009 fall 
supplements in Medicare Beneficiary Survey. Medication and comorbidity informa-
tion were collected from Medicare claims data. Sedative-hypnotic drugs consisted of 
antidepressants with sedating properties, benzodiazepines, and non-benzodiazepine 
hypnotics. Total drug day supply was calculated for each beneficiary to indirectly 
observe cumulative dose effect. Logistic regression was conducted to assess the asso-
ciation between sedative-hypnotic use and falls. RESULTS: A total 2,823 beneficiaries 
were included in the study. Proportion of those who reported past year fall were 33% 
for users and 21% for non-users (p< 0.01). When adjusted for socio-demographic and 
other covariates, sedative-hypnotic users were 1.5 times more likely to report a fall 
past year (OR 1.5, 1.2-2.0[PY1]); and 1.9 times for users with > 1 sedative-hypnotic 
drug class (1.9, 1.2-3.0). Only the users with < 90 day supply of sedative-hypnotics 
showed no increase in odds for past year fall. CONCLUSIONS: Sedative-hypnotic 
use was associated with increased risk of falls among older adults. Short-term use 
(< 90 day supply) of sedative-hypnotic drugs may provide a safer treatment strategy 
for this population. [PY1]95% confidence interval is provided for each odds ratio (OR)
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OBJECTIVES: To use electronic health records (EHR) data to evaluate relationships 
of serum uric acid (SrUA) levels with hypertension and hyperlipidemia in patients 
with gout. METHODS: This retrospective study used de-identified EHR data from 
the Humedica database between 2010 and 2013. Patients were adults (≥ 18 years) 
with ≥ 2 ICD-9-CM diagnosis codes for gout ≥ 30 days apart (first diagnosis = index 
event), with ≥ 1 SrUA assessments, and ≥ 6 months pre- and ≥ 12 months post-index 
activity. Hypertension and hyperlipidemia were based on ICD-9 codes; patients with 
a hypertension or hyperlipidemia diagnosis during the 6-month pre-index period 
were excluded. Patients were stratified by SrUA quartiles: 0.01-4.0mg/dL (n= 2730), 
4.1-6.0mg/dL (n= 4349), 6.1-8.0mg/dL (n= 6136), and ≥ 8.1mg/dL (n= 5744). RESULTS: 
Patients were male (76.8%), white (81.1%) with mean±SD age of 60.5±14.1 years and 
mean±SD Charlson Comorbidity Index of 0.63±1.20. There were no significant differ-
ences across SrUA quartiles for proportions of patients diagnosed with hyperlipidemia 
12-months post-index, which ranged from 37.6% (4.1-6.0mg/dL) to 38.2% (0.01-4.0mg/
dL). In contrast, the ≥ 8.1mg/dL quartile had a significantly higher incidence of hyper-
tension, 60.3% (P< 0.001 versus all other quartiles), and the 0.01-4.0mg/dL quartile was 
significantly greater relative to the 4.1-6.0mg/dL quartile (56.1% vs 53.6%; P< 0.05) 
but similar to the 6.1-8.0mg/dL quartile (54.5%). The diagnosis of hypertension or 
